Operative management for recurrent and metastatic adrenocortical carcinoma

Nicole M. Datrice, Russell C. Langan, R. Taylor Ripley, Clinton D. Kemp, Seth M. Steinberg, Bradford J. Wood, Steven K. Libutti, Tito Fojo, David S. Schrump, Itzhak Avital

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective A review of all resections for recurrent or metastatic ACC was performed to identify patients who might benefit from a surgical approach, and to identify factors that might aid in prognosis among patients with metastatic disease. Summary Background Data Adrenocortical carcinoma (ACC) is a rare tumor, with frequent recurrences and metastases even after complete resection. Chemotherapy has limited efficacy, and surgical resection of metastatic ACC remains controversial. Methods A retrospective review was performed of all patients who underwent surgical intervention for metastatic ACC in a single tertiary center from 1977 to 2009. All available clinicopathologic data were analyzed to determine potential factors associated with response to treatment and survival. Results Fifty-seven patients underwent 116 procedures for recurrent or metastatic disease. Twenty-three resections were for liver metastases, 48 for pulmonary metastases, 22 for abdominal disease including local recurrences, and 13 were for metastases at other sites. Median and 5-year survivals from time of first metastasectomy were 2.5 years, and 41%, respectively. The median survival of patients with DFI <12 months was 1.7 years, compared to 6.6 years for patients with DFI >12 months (P=0.015). Median survival for right versus left-sided primaries was 1.9 years versus 3.8 years (P=0.03). Liver metastases were more common with right-sided primaries (67% vs. 41%, P=0.05). Chemotherapy had no impact on survival. Conclusions Resection of recurrent or metastatic ACC is safe, and may result in prolongation of survival in selected patients with DFI greater than 1 year.

Original languageEnglish (US)
Pages (from-to)709-713
Number of pages5
JournalJournal of Surgical Oncology
Volume105
Issue number7
DOIs
StatePublished - Jun 1 2012

Fingerprint

Adrenocortical Carcinoma
Survival
Neoplasm Metastasis
Metastasectomy
Recurrence
Drug Therapy
Liver
Lung
Neoplasms

Keywords

  • and lung resection
  • liver resection
  • metastatic adrenocortical carcinoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Datrice, N. M., Langan, R. C., Ripley, R. T., Kemp, C. D., Steinberg, S. M., Wood, B. J., ... Avital, I. (2012). Operative management for recurrent and metastatic adrenocortical carcinoma. Journal of Surgical Oncology, 105(7), 709-713. https://doi.org/10.1002/jso.23015

Operative management for recurrent and metastatic adrenocortical carcinoma. / Datrice, Nicole M.; Langan, Russell C.; Ripley, R. Taylor; Kemp, Clinton D.; Steinberg, Seth M.; Wood, Bradford J.; Libutti, Steven K.; Fojo, Tito; Schrump, David S.; Avital, Itzhak.

In: Journal of Surgical Oncology, Vol. 105, No. 7, 01.06.2012, p. 709-713.

Research output: Contribution to journalArticle

Datrice, NM, Langan, RC, Ripley, RT, Kemp, CD, Steinberg, SM, Wood, BJ, Libutti, SK, Fojo, T, Schrump, DS & Avital, I 2012, 'Operative management for recurrent and metastatic adrenocortical carcinoma', Journal of Surgical Oncology, vol. 105, no. 7, pp. 709-713. https://doi.org/10.1002/jso.23015
Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ et al. Operative management for recurrent and metastatic adrenocortical carcinoma. Journal of Surgical Oncology. 2012 Jun 1;105(7):709-713. https://doi.org/10.1002/jso.23015
Datrice, Nicole M. ; Langan, Russell C. ; Ripley, R. Taylor ; Kemp, Clinton D. ; Steinberg, Seth M. ; Wood, Bradford J. ; Libutti, Steven K. ; Fojo, Tito ; Schrump, David S. ; Avital, Itzhak. / Operative management for recurrent and metastatic adrenocortical carcinoma. In: Journal of Surgical Oncology. 2012 ; Vol. 105, No. 7. pp. 709-713.
@article{226d789c32454e80a4fae98ae528f069,
title = "Operative management for recurrent and metastatic adrenocortical carcinoma",
abstract = "Objective A review of all resections for recurrent or metastatic ACC was performed to identify patients who might benefit from a surgical approach, and to identify factors that might aid in prognosis among patients with metastatic disease. Summary Background Data Adrenocortical carcinoma (ACC) is a rare tumor, with frequent recurrences and metastases even after complete resection. Chemotherapy has limited efficacy, and surgical resection of metastatic ACC remains controversial. Methods A retrospective review was performed of all patients who underwent surgical intervention for metastatic ACC in a single tertiary center from 1977 to 2009. All available clinicopathologic data were analyzed to determine potential factors associated with response to treatment and survival. Results Fifty-seven patients underwent 116 procedures for recurrent or metastatic disease. Twenty-three resections were for liver metastases, 48 for pulmonary metastases, 22 for abdominal disease including local recurrences, and 13 were for metastases at other sites. Median and 5-year survivals from time of first metastasectomy were 2.5 years, and 41{\%}, respectively. The median survival of patients with DFI <12 months was 1.7 years, compared to 6.6 years for patients with DFI >12 months (P=0.015). Median survival for right versus left-sided primaries was 1.9 years versus 3.8 years (P=0.03). Liver metastases were more common with right-sided primaries (67{\%} vs. 41{\%}, P=0.05). Chemotherapy had no impact on survival. Conclusions Resection of recurrent or metastatic ACC is safe, and may result in prolongation of survival in selected patients with DFI greater than 1 year.",
keywords = "and lung resection, liver resection, metastatic adrenocortical carcinoma",
author = "Datrice, {Nicole M.} and Langan, {Russell C.} and Ripley, {R. Taylor} and Kemp, {Clinton D.} and Steinberg, {Seth M.} and Wood, {Bradford J.} and Libutti, {Steven K.} and Tito Fojo and Schrump, {David S.} and Itzhak Avital",
year = "2012",
month = "6",
day = "1",
doi = "10.1002/jso.23015",
language = "English (US)",
volume = "105",
pages = "709--713",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Operative management for recurrent and metastatic adrenocortical carcinoma

AU - Datrice, Nicole M.

AU - Langan, Russell C.

AU - Ripley, R. Taylor

AU - Kemp, Clinton D.

AU - Steinberg, Seth M.

AU - Wood, Bradford J.

AU - Libutti, Steven K.

AU - Fojo, Tito

AU - Schrump, David S.

AU - Avital, Itzhak

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Objective A review of all resections for recurrent or metastatic ACC was performed to identify patients who might benefit from a surgical approach, and to identify factors that might aid in prognosis among patients with metastatic disease. Summary Background Data Adrenocortical carcinoma (ACC) is a rare tumor, with frequent recurrences and metastases even after complete resection. Chemotherapy has limited efficacy, and surgical resection of metastatic ACC remains controversial. Methods A retrospective review was performed of all patients who underwent surgical intervention for metastatic ACC in a single tertiary center from 1977 to 2009. All available clinicopathologic data were analyzed to determine potential factors associated with response to treatment and survival. Results Fifty-seven patients underwent 116 procedures for recurrent or metastatic disease. Twenty-three resections were for liver metastases, 48 for pulmonary metastases, 22 for abdominal disease including local recurrences, and 13 were for metastases at other sites. Median and 5-year survivals from time of first metastasectomy were 2.5 years, and 41%, respectively. The median survival of patients with DFI <12 months was 1.7 years, compared to 6.6 years for patients with DFI >12 months (P=0.015). Median survival for right versus left-sided primaries was 1.9 years versus 3.8 years (P=0.03). Liver metastases were more common with right-sided primaries (67% vs. 41%, P=0.05). Chemotherapy had no impact on survival. Conclusions Resection of recurrent or metastatic ACC is safe, and may result in prolongation of survival in selected patients with DFI greater than 1 year.

AB - Objective A review of all resections for recurrent or metastatic ACC was performed to identify patients who might benefit from a surgical approach, and to identify factors that might aid in prognosis among patients with metastatic disease. Summary Background Data Adrenocortical carcinoma (ACC) is a rare tumor, with frequent recurrences and metastases even after complete resection. Chemotherapy has limited efficacy, and surgical resection of metastatic ACC remains controversial. Methods A retrospective review was performed of all patients who underwent surgical intervention for metastatic ACC in a single tertiary center from 1977 to 2009. All available clinicopathologic data were analyzed to determine potential factors associated with response to treatment and survival. Results Fifty-seven patients underwent 116 procedures for recurrent or metastatic disease. Twenty-three resections were for liver metastases, 48 for pulmonary metastases, 22 for abdominal disease including local recurrences, and 13 were for metastases at other sites. Median and 5-year survivals from time of first metastasectomy were 2.5 years, and 41%, respectively. The median survival of patients with DFI <12 months was 1.7 years, compared to 6.6 years for patients with DFI >12 months (P=0.015). Median survival for right versus left-sided primaries was 1.9 years versus 3.8 years (P=0.03). Liver metastases were more common with right-sided primaries (67% vs. 41%, P=0.05). Chemotherapy had no impact on survival. Conclusions Resection of recurrent or metastatic ACC is safe, and may result in prolongation of survival in selected patients with DFI greater than 1 year.

KW - and lung resection

KW - liver resection

KW - metastatic adrenocortical carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84859884713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859884713&partnerID=8YFLogxK

U2 - 10.1002/jso.23015

DO - 10.1002/jso.23015

M3 - Article

VL - 105

SP - 709

EP - 713

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 7

ER -